Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies

Blood Reviews

Volumn 27, Issue 2, 2013, Pages 103-109

  Teitel, Jerome M ^a   Sholzberg, Michelle ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Activated prothrombin complex concentrates; Factor VIIa; Factor VIII inhibitors; Hemophilia; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; DRUG ANTIBODY; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TRANEXAMIC ACID;

ANTIBODY TITER; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; DRUG CLEARANCE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; INTRAMUSCULAR BLEEDING; JOINT DESTRUCTION; LOW DRUG DOSE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOFT TISSUE BLEEDING; THROMBOEMBOLISM; THROMBOSIS;

BLOOD COAGULATION FACTORS; FACTOR VIII; HEMOPHILIA A; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84875258603     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.02.003     Document Type: Article

References (100)

1. Ehrenforth S., Kreuz W., Scharrer I., Linde R., Funk M., Güngör T., et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992, 339:594-598.
2. Kreuz W., Becker S., Lenz E., Martinez-Saguer I., Escuriola-Ettingshausen C., Funk M., et al. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII. Semin Thromb Hemost 1995, 21:382-389.
3. Gouw S.C., van den Berg H.M., Oldenburg J., Astermark J., de Groot P.G., Margaglione M., et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012, 119:2922-2934.
4. Astermark J., Oldenburg J., Escobar M., White G.C., Berntorp E. The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005, 90:924-931.
5. Astermark J., Oldenburg J., Pavlova A., Berntorp E., Lefvert A.K. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006, 107:3167-3172.
6. Astermark J., Oldenburg J., Carlson J., Pavlova A., Kavakli K., Berntorp E., et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006, 108:3739-3745.
7. Pavlova A., DeLeve D., Lacroix-Desmazes S., Schwaab R., Mende M., Fimmers R., et al. Impact of polymorphism of the major histocompatibility complex class II, interleukin 10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009, 7:2006-2015.
8. Gouw S.C., Van der Bom J.G., Auerswald G., Ettinghausen C.E., Tedgard U., Van den Berg H.M. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007, 109:4693-4697.
9. Collins P.W. Inhibitors, what is the risk of treatment intensity?. J Thromb Haemost 2007, 5:1380-1382.
10. Gouw S.C., Van der Bom J.G., Marijke van den B.H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007, 109:4648-4654.
11. Kurnik K., Bidlingmaier C., Engl W., Chehadeh H., Reipert B., Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010, 16:256-262.
12. Kreuz W., Ettingshausen C.E., Zyschka A., Oldenburg J., Saguer I.M., Ehrenforth S., et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost 2002, 28:285-290.
13. Collins P.W., Hirsch S., Baglin T.P., Dolan G., Hanley J., Makris M., et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007, 109:1870-1877.
14. Knoebl P., Marco P., Baudo F., Collins P., Huth-Kuhne A., Nemes L., et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012, 10:622-631.
15. Hay C.R.M., Baglin T.P., Collins P.W., Hill F.G.H., Keeling D.M. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol 2000, 111:78-90.
16. Breen F.A., Tullis J.L. Prothrombin concentrates in treatment of Christmas disease and allied disorders. JAMA 1969, 208:1848-1852.
17. Fekete L.F., Holst S.L., Peetroom F. Auto-factor IX concentrate: a new therapeutic approach to treatment of hemophilia A patients with inhibitors. XIV Congress of the International Society of Hematology 1972, [p. abstr 295].
18. Abildgaard C.F., Britton M., Harrison J. Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitors. J Pediatr 1976, 88:200-205.
19. Kelly P., Penner J.A. Antihemophilic factor inhibitors. Management with prothrombin complex concentrates. JAMA 1976, 236:2061-2064.
20. Buchanan G.R., Kevy S.V. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies. Pediatrics 1978, 62:767-774.
21. Blatt P.M., Menache D., Roberts H.R. A survey of the effectiveness of prothrombin complex concentrates in controlling hemorrhage in patients with hemophilia and anti-Factor VIII antibodies. Thromb Haemost 1980, 44:39-42.
22. Lusher J.M., Shapiro S.S., Palascak J.E., Rao A.V., Levine P.H., Blatt P.M. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med 1980, 303:421-425.
23. Eyster M.E., Spero J.A., Catalano P.M., Gill F.M., Lusch C.J., Kajani M.K., et al. Inhibitor treatment using unactivated prothrombin complex concentrates: the Pennsylvania experience-1978-1982. Prog Clin Biol Res 1984, 150:309-322.
24. Lusher J.M., Blatt P.M., Penner J.A., Aledort L.M., Levine P.H., White G.C., et al. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983, 62:1135-1138.
25. Seligsohn U., Kasper C.K., Osterud B., Rapaport S.I. Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979, 53:828-837.
26. Kurczynski E.M., Penner J.A. Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med 1974, 291:164-167.
27. Stenbjerg S., Jorgensen J. Resistance to activated F IX concentrate (FEIBA). Scand J Haematol 1977, 18:421-426.
28. Sjamsoedin L.J., Heijnen L., Mauser-Bunschoten E.P., van Geijlswijk J.L., van Houwelingen H., van Asten P., et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981, 305:717-721.
29. Perry D., Berntorp E., Tait C., Dolan G., Holme P.A., Laffan M., et al. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations. Haemophilia 2010, 16:80-89.
30. Astermark J., Donfield S.M., DiMichele D.M., Gringeri A., Gilbert S.A., Waters J., et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007, 109:546-551.
31. Turecek P.L., Varadi K., Gritsch H., Auer W., Pichler L., Eder G., et al. Factor Xa and prothrombin: mechanism of action of FEIBA. Vox Sang 1999, 77(Suppl. 1):72-79.
32. Hedner U., Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983, 71:1836-1841.
33. Hedner U., Bjoern S., Bernvil S.S., Tengborn L., Stigendahl L. Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. Haemostasis 1989, 19:335-343.
34. Chabbat J., Hampikian-Lenin S., Toully V., Gaillandre A., Pejaudier L., Steinbuch M. A human factor VIIa concentrate and its effects in the hemophilic A dog. Thromb Res 1989, 54:603-612.
35. Macik B.G., Hohneker J., Roberts H.R., Griffin A.M. Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor. Am J Hematol 1989, 32:232-234.
36. Roberts H.R., Monroe D.M., White G.C. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004, 104:3858-3864.
37. Kulkarni R., Aledort L.M., Berntorp E., Brackman H.H., Brown D., Cohen A.R., et al. Therapeutic choices for patients with hemophilia and high-titer inhibitors. Am J Hematol 2001, 67:240-246.
38. Persson E. Novel molecules for the correction of factor Xa generation and phenotype in hemophilia. Thromb Res 2012, 129:S51-S53.
39. Tranholm M., Kristensen K., Kristensen A.T., Pyke C., Rojkjaer R., Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 2003, 102:3615-3620.
40. Negrier C., Dargaud Y., Bordet J.C. Basic aspects of bypassing agents. Haemophilia 2006, 12(Suppl. 6):48-52.
41. Hoffman M., Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 2012, 10:1478-1485.
42. Kempton C.L., Abshire T.C., Deveras R.A., Hoots W.K., Gill J.C., Kessler C.M., et al. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia 2012, 18:798-804.
43. DiMichele D., Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006, 12:352-362.
44. Abshire T., Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004, 2:899-909.
45. Ehrlich H.J., Henzl M.J., Gomperts E.D. Safety of factor VIII inhibitor bypass activity (FEIBA(R)): 10-year compilation of thrombotic adverse events. Haemophilia 2002, 8:83-90.
46. Abshire T., Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008, 14:898-902.
47. Baglin T. The measurement and application of thrombin generation. Br J Haematol 2005, 130:653-661.
48. Parameswaran R., Shapiro A.D., Gill J.C., Kessler C.M. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005, 11:100-106.
49. Van Creveld S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol 1971, 45:120-127.
50. Aledort L.M., Haschmeyer R.H., Pettersson H. Orthopedic Outcome Study G. A longitudinal study of orthopaedic outcomes for severe factor VIII deficient haemophiliacs. J Int Med 1994, 236:391-399.
51. Nilsson I.M., Berntorp E., Löfqvist T., Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992, 232:25-32.
52. Fischer K., Van der Bom J.G., Molho P., Negrier C., Mauser-Bunschoten E.P., Roosendaal G., et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002, 8:745-752.
53. Manco-Johnson M.J., Abshire T.C., Shapiro A.D., Riske B., Hacker M.R., Kilcoyne R., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-544.
54. Hay C.R., Brown S., Collins P.W., Keeling D.M., Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006, 133:591-605.
55. Negrier C., Goudemand J., Sultan Y., Bertrand M., Rothschild C., Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997, 77:1113-1119.
56. Hay C.R., Dimichele D.M. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012, 119:1335-1344.
57. Gringeri A., Musso R., Mazzucconi M.G., Piseddu G., Schiavoni M., Pignoloni P., et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007, 13:373-379.
58. DiMichele D.M., Hoots W.K., Pipe S.W., Rivard G.E., Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007, 13(Suppl. 1):1-22.
59. Lindley C.M., Sawyer W.T., Macik B.G., Lusher J., Harrison J.F., Baird-Cox K., et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994, 55:638-648.
60. Villar A., Aronis S., Morfini M., Santagostino E., Auerswald G., Thomsen H.F., et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004, 10:352-359.
61. Brackmann H.H., Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977, 2:933.
62. Brackmann H.H., Oldenburg J., Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years' 'Bonn protocol'. Vox Sang 1996, 70(Suppl. 1):30-35.
63. Brackmann H., Lenk H., Scharrer I., Auerswald G., Kreuz W. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999, 5:203-206.
64. Gringeri A., Mannucci P.M. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005, 11:611-619.
65. Klintman J., Astermark J., Berntorp E. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma. Br J Haematol 2010, 151:381-386.
66. Jimenez-Yuste V., Alvarez M.T., Martin-Salces M., Quintana M., Rodriguez-Merchan C., Lopez-Cabarcos C., et al. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia 2009, 15:203-209.
67. Valentino L.A. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia 2009, 15:733-742.
68. Kreuz W., Escuriola-Ettinghausen C., Mentzer D., Martinez I., Becker S., Stoll H., et al. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors. Blood 2000, 96:266a.
69. Franchini M., Lippi G. Immune tolerance induction for patients with severe hemophilia A: a critical literature review. J Thromb Thrombolysis 2011, 32:439-447.
70. Coppola A., Di Minno M.N., Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010, 150:515-528.
71. DiMichele D. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 2009, 15:320-328.
72. Benson G., Auerswald G., Elezovic I., Lambert T., Ljung R., Morfini M., et al. Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice. Eur J Haematol 2012, 88:371-379.
73. Astermark J., Morado M., Rocino A., van den Berg H.M., von Depka M., Gringeri A., et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006, 12:363-371.
74. Valentino L.A., Carcao M., Mathew P., Leissinger C.A., Berntorp E., Blanchette V., et al. The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report. Haemophilia 2009, 15:959-965.
75. Berntorp E., Shapiro A., Astermark J., Blanchette V.S., Collins P.W., Dimichele D., et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006, 12(Suppl. 6):1-7.
76. Morfini M., Auerswald G., Kobelt R.A., Rivolta G.F., Rodriguez-Martorell J., Scaraggi F.A., et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007, 13:502-507.
77. Brackmann H.H., Effenberger E., Hess L., Schwaab R., Oldenburg J. NovoSeven in immune tolerance therapy. Blood Coagul Fibrinolysis 2000, 11(Suppl. 1):S39-S44.
78. Valentino L.A. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia 2010, 16:263-271.
79. Leissinger C.A., Becton D.L., Ewing N.P., Valentino L.A. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007, 13:249-255.
80. Hilgartner M.W., Makipernaa A., DiMichele D.M. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003, 9:261-268.
81. Ohga S., Nomura A., Takada H., Suga N., Hara T. Successful self-infusion of activated prothrombin complex concentrate for prophylaxis in a child with a factor VIII inhibitor. Am J Hematol 2007, 82:145-149.
82. Siegmund B., Richter H., Pollmann H. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?. Haemophilia 2005, 11:638-641.
83. Ettingshausen C.E., Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series. Haemophilia 2010, 16:90-100.
84. Leissinger C., Gringeri A., Antmen B., Berntorp E., Biasoli C., Carpenter S., et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011, 365:1684-1692.
85. Gringeri A. Pharmacoeconomic evaluation with an activated prothrombin complex coNcentrate (APCC) in patients with hemophilia and inhibitors (PROFEIBA Study). Haemophilia 2012, 18.
86. Berntorp E., Figueiredo S., Futema L., Pock K., Knaub S., Walter O., et al. A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors. Blood Coagul Fibrinolysis 2010, 21:577-583.
87. Yolken R.H., Hilgartner M.W. Prothrombin complex concentrates. Use in treatment of hemophiliacs with factor VIII inhibitors. Am J Dis Child 1978, 132:291-293.
88. Leissinger C.A. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999, 5(Suppl. 3):25-32.
89. Allain J.P., Krieger G.R. Letter: Prothrombin-complex concentrate in treatment of classical haemophilia with factor-VIII antibody. Lancet 1975, 2:1203.
90. Kasper C.K. Effect of prothrombin complex concentrates on factor VIII inhibitor levels. Blood 1979, 54:1358-1368.
91. Wolberg A.S., Allen G.A., Monroe D.M., Hedner U., Roberts H.R., Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005, 131:645-655.
92. Hedner U. Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors. J Thromb Haemost 2006, 4:2498-2500.
93. Saxon B.R., Shanks D., Jory C.B., Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost 2001, 86:1126-1127.
94. Blatny J., Kohlerova S., Zapletal O., Fiamoli V., Penka M., Smith O. Prophylaxis with recombinant factor VIIa for the management of bleeding episodes during immune tolerance treatment in a boy with severe haemophilia A and high-response inhibitors. Haemophilia 2008, 14:1140-1142.
95. Young G., McDaniel M., Nugent D.J. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 2005, 11:203-207.
96. Konkle B.A., Ebbesen L.S., Erhardtsen E., Bianco R.P., Lissitchkov T., Rusen L., et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007, 5:1904-1913.
97. Hoots W.K., Ebbesen L.S., Konkle B.A., Auerswald G.K., Roberts H.R., Weatherall J., et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008, 14:466-475.
98. Young G., Auerswald G., Jimenez-Yuste V., Lambert T., Morfini M., Santagostino E., et al. PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res 2012, 130:864-870.
99. Schramm W., Royal S., Kroner B., Berntorp E., Giangrande P., Ludlam C., et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002, 8:33-43.
100. Teitel J., Berntorp E., Dolan G., Fischer K., Gringeri A., Kessler C., et al. A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients. Haemophilia 2011, 17:516-521.